Jordan, K, Proskorovsky, I, Lewis, P, Ishak, J, Payne, K, Lordan, N, Kyriakou, C, Williams, CD, Peters, S, Davies, FE. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health‐related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 2013, 22:417–426.
Ferlay, J, Shin, H‐R, Bray, F, Forman, D, Mathers, C, Parkin, DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893–2917.
Ferlay, J, Shin, H‐R, Bray, F, Forman, D, Mathers, C, Parkin, DM. GLOBOCAN 2008 v3.0, cancer incidence and mortality worldwide: IARC CancerBase No. 10, Lyon, France; 2010. Available at: http://globocan.iarc.fr. (Accessed April 24, 2014).
Gottesman, MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615–627.
Cutts, JH, Beer, CT, Noble, RL. Biological properties of Vincaleukoblastine, an alkaloid in Vinca Rosea Linn, with reference to its antitumor action. Cancer Res 1960, 20:1023–1031.
Wani, MC, Taylor, HL, Wall, ME, Coggon, P, McPhail, AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325–2327.
Tan, C, Tasaka, H, Yu, KP, Murphy, ML, Karnofsky, DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967, 20:333–353.
Zahreddine, H, Borden, KLB. Mechanisms and insights into drug resistance in cancer. Front Pharmacol 2013, 4:28.
Baguley, BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010, 46:308–316.
Gillet, J‐P, Gottesman, MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010, 596:47–76.
Meads, MB, Gatenby, RA, Dalton, WS. Environment‐mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665–674.
Nguyen, LV, Vanner, R, Dirks, P, Eaves, CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133–143.
Callaghan, R, George, AM, Kerr, ID. Molecular aspects of the translocation process by ABC proteins. Comp Biophys 2012, 8:145–173.
Juliano, RL, Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152–162.
Eckford, PDW, Sharom, FJ. ABC efflux pump‐based resistance to chemotherapy drugs. Chem Rev 2009, 109:2989–3011.
Yamagishi, T, Sahni, S, Sharp, DM, Arvind, A, Jansson, PJ, Richardson, DR. P‐glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 2013, 288:31761–31771.
Ford, RC, Kamis, AB, Kerr, ID, Callaghan, R. %22The ABC transporters: structural insights into drug transport%22. In: Ecker, G, Chiba, P, eds. Transporters as Drug Carriers. Methods and Principles in Medicinal Chemistry, vol. 44. Weinheim: Wiley‐VCH; 2009, 3–48.
Dawson, RJP, Locher, KP. Structure of a bacterial multidrug ABC transporter. Nature 2006, 443:180–185.
Sharom, FJ, Liu, R, Qu, Q, Romsicki, Y. Exploring the structure and function of the P‐glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol 2001, 12:257–265.
Rosenberg, MF, Callaghan, R, Modok, S, Higgins, CF, Ford, RC. Three‐dimensional structure of P‐glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide‐bound state. J Biol Chem 2005, 280:2857–2862.
Locher, KP. Structure and mechanism of ATP‐binding cassette transporters. Philos Trans R Soc Lond B 2009, 364:239–245.
Sharom, FJ, Lugo, MR, Eckford, PDW. New insights into the drug binding, transport and lipid flippase activities of the P‐glycoprotein multidrug transporter. J Bioenerg Biomembr 2005, 37:481–487.
Vanakker, OM, Hosen, MJ, Paepe, AD. The ABCC6 transporter: what lessons can be learnt from other ATP‐binding cassette transporters? Front Genet 2013, 4:203.
Borges‐Walmsley, MI, McKeegan, KS, Walmsley, AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem J 2003, 376:313–338.
Sharom, FJ. The P‐glycoprotein multidrug transporter. Essays Biochem 2011, 50:161–178.
Van Assema, DME, Lubberink, M, Bauer, M, van der Flier, WM, Schuit, RC, Windhorst, AD, Comans, EFI, Hoetjes, NJ, Tolboom, N, Langer, O, et al. Blood‐brain barrier P‐glycoprotein function in Alzheimer`s disease. Brain 2012, 135:181–189.
Lam, FC, Liu, R, Lu, P, Shapiro, AB, Renoir, JM, Sharom, FJ, Reiner, PB. β‐Amyloid efflux mediated by P‐glycoprotein. J Neurochem 2001, 76:1121–1128.
Kuhnke, D, Jedlitschky, G, Grube, M, Krohn, M, Jucker, M, Mosyagin, I, Cascorbi, I, Walker, LC, Kroemer, HK, Warzok, RW, et al. MDR1‐P‐glycoprotein (ABCB1) mediates transport of Alzheimer`s amyloid‐β peptides—implications for the mechanisms of Abeta clearance at the blood‐brain barrier. Brain Pathol 2007, 17:347–353.
Orlowski, S, Martin, S, Escargueil, A. P‐glycoprotein and “lipid rafts”: some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci 2006, 63:1038–1059.
Higgins, CF, Gottesman, MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992, 17:18–21.
Eckford, PDW, Sharom, FJ. The reconstituted P‐glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem J 2005, 389:517–526.
Shapiro, AB, Fox, K, Lam, P, Ling, V. Stimulation of P‐glycoprotein‐mediated drug transport by prazosin and progesterone. Eur J Biochem 2001, 259:841–850.
Kwon, Y, Kamath, AV, Morris, ME. Inhibitors of P‐glycoprotein‐mediated daunomycin transport in rat liver canalicular membrane vesicles. J Pharm Sci 1996, 85:935–939.
Rosenberg, MF, Mao, Q, Holzenburg, A, Ford, RC, Deeley, RG, Cole, SP. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). Crystallization and single‐particle analysis. J Biol Chem 2001, 276:16076–16082.
Miyake, K, Mickley, L, Litman, T, Zhan, Z, Robey, R, Cristensen, B, Brangi, M, Greenberger, L, Dean, M, Fojo, T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone‐resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999, 59:8–13.
Mo, W, Zhang, J‐T. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012, 3:1–27.
Jardetzky, O. Simple allosteric model for membrane pumps. Nature 1966, 211:969–970.
Sharom, FJ. The P‐glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997, 160:161–175.
Callaghan, R, Ford, RC, Kerr, ID. The translocation mechanism of P‐glycoprotein. FEBS Lett 2006, 580:1056–1063.
Ambudkar, SV, Kim, I, Sauna, ZE. The power of the pump: mechanisms of action of P‐glycoprotein (ABCB1). Eur J Pharm Sci 2006, 27:392–400.
Altenberg, GA, Vanoye, CG, Horton, JK, Reuss, L, Julie, K. Unidirectional fluxes of rhodamine 123 in multidrug‐resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci U S A 1994, 91:4654–4657.
Homolya, L, Holló, Z, Germann, UA, Pastan, I, Gottesman, MM, Sarkadi, B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993, 268:21493–21496.
Romsicki, Y, Sharom, FJ. The membrane lipid environment modulates drug interactions with the P‐glycoprotein multidrug transporter. Biochemistry 1999, 38:6887–6896.
Wang, RB, Kuo, CL, Lien, LL, Lien, EJ‐C. Structure‐activity relationship: analyses of P‐glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003, 28:203–228.
Lu, P, Liu, R, Sharom, FJ. Drug transport by reconstituted P‐glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur J Biochem 2001, 268:1687–1697.
Raviv, Y, Pollard, HB, Bruggemann, EP, Pastan, I, Gottesman, MM. Photosensitized labeling of a functional multidrug transporter in living drug‐resistant tumor cells. J Biol Chem 1990, 265:3975–3980.
Senior, AE, Al‐Shawi, MK, Urbatsch, IL. The catalytic cycle of P‐glycoprotein. FEBS Lett 1995, 377:285–289.
Urbatsch, IL, Senior, AE. Effects of lipids on ATPase activity of purified Chinese hamster P‐glycoprotein. Arch Biochem Biophys 1995, 316:135–140.
Shapiro, AB, Corder, AB, Ling, V. P‐glycoprotein‐mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 1997, 250:115–121.
Shapiro, AB, Ling, V. Transport of LDS‐751 from the cytoplasmic leaflet of the plasma membrane by the Rhodamine‐123‐selective site of P‐glycoprotein. Eur J Biochem 1998, 254:181–188.
Shapiro, AB, Ling, V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P‐glycoprotein. Biochem Pharmacol 1997, 53:587–596.
Parveen, Z, Stockner, T, Bentele, C, Pferschy, S, Kraupp, M, Freissmuth, M, Ecker, GF, Chiba, P. Molecular dissection of dual pseudosymmetric solute translocation pathways in human P‐glycoprotein. Mol Pharmacol 2011, 79:443–452.
Shapiro, AB, Ling, V. Positively cooperative sites for drug transport by P‐glycoprotein with distinct drug specificities. Eur J Biochem 1997, 250:130–137.
Tsuruo, T, Lida, H, Tsukagoshi, S, Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 141:1967–1972.
Tsuruo, T, Iida, H, Kitatani, Y, Yokota, K, Tsukagoshi, S, Sakurai, Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug‐resistant tumor cells. Cancer Res 1984, 44:4303–4307.
Twentyman, PR, Fox, NE, White, DJ. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi‐drug resistant human lung cancer cell line. Br J Cancer 1987, 56:55–57.
Höllt, V, Kouba, M, Dietel, M, Vogt, G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P‐glycoprotein. Biochem Pharmacol 1992, 43:2601–2608.
Hofmann, J, Gekeler, V, Ise, W, Noller, A, Mitterdorfer, J, Hofer, S, Utz, I, Gotwald, M, Boer, R, Glossmann, H. Mechanism of action of dexniguldipine‐HCl (B8509‐035), a new potent modulator of multidrug resistance. Biochem Pharmacol 1995, 49:603–609.
Peck, RA, Hewett, J, Harding, MW, Wang, YM, Chaturvedi, PR, Bhatnagar, A, Ziessman, H, Atkins, F, Hawkins, MJ. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001, 19:3130–3141.
Nüssler, V, Pelka‐Fleisc, R, Gieseler, F, Hasmann, M, Löser, R, Gullis, E, Stötzer, O, Zwierzina, H, Wilmanns, W. In vitro efficacy of known P‐glycoprotein modulators compared to droloxifene E and Z: studies on a human T‐cell leukemia cell line and their resistant variants. Leuk Lymphoma 1998, 31:589–597.
Palmeira, A, Sousa, E, Vasconcelos, MH, Pinto, M. Three decades of P‐Gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012, 19:1946–2025.
Martin, C, Berridge, G, Mistry, P, Higgins, CF, Charlton, P, Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein. Br J Pharmacol 1999, 128:403–411.
Hyafil, F, Vergely, C, Du Vignaud, P, Grand‐Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53:4595–4602.
Dantzig, AH, Shepard, RL, Cao, J, Law, KL, Ehlhardt, WJ, Baughman, TM, Bumol, TF, Starling, JJ. Reversal of P‐glycoprotein‐mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996, 56:4171–4179.
Van Zuylen, L, Sparreboom, A, van der Gaast, A, van der Burg, ME, van Beurden, V, Bol, CJ, Woestenborghs, R, Palmer, PA, Verweij, J. The orally administered P‐glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 2000, 6:1365–1371.
Conseil, G, Baubichon‐Cortay, H, Dayan, G, Jault, J‐M, Barron, D, Pietro, AD, Di Pietro, A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP‐ and steroid‐binding sites on mouse P‐glycoprotein. Proc Natl Acad Sci U S A 1998, 95:9831–9836.
Reis, MA, Ferreira, RJ, Santos, MMM, dos Santos, DJVA, Molnár, J, Ferreira, M‐JU. Enhancing macrocyclic diterpenes as multidrug‐resistance reversers: structure‐activity studies on Jolkinol D derivatives. J Med Chem 2013, 56:748–760.
Ramalhete, C, Molnár, J, Mulhovo, S, Rosário, VE, Ferreira, M‐JU. New potent P‐glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells. Bioorg Med Chem 2009, 17:6942–6951.
Rautio, J, Humphreys, JE, Webster, LO, Balakrishnan, A, Keogh, JP, Kunta, JR, Serabjit‐Singh, CJ, Polli, JW. In vitro P‐glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006, 34:786–792.
Hendrich, A, Michalak, K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Pharm Res 2003, 4:23–30.
Palmeira, A, Sousa, E, Vasconcelos, H, Pinto, M, Fernandes, MX. Structure and ligand‐based design of P‐glycoprotein inhibitors: a historical perspective. Curr Pharm Des 2012, 18:4197–4224.
Liu, H, Ma, Z, Wu, B. Structure‐activity relationships and in silico models of P‐glycoprotein (ABCB1) inhibitors. Xenobiotica 2013, 43:1018–1026.
Aller, SG, Yu, J, Ward, A, Weng, Y, Chittaboina, S, Zhuo, R, Harrell, PM, Trinh, YT, Zhang, Q, Urbatsch, IL, et al. Structure of P‐glycoprotein reveals a molecular basis for poly‐specific drug binding. Science 2009, 323:1718–1722.
Ward, AB, Szewczyk, P, Grimard, V, Lee, C‐W, Martinez, L, Doshi, R, Caya, A, Villaluz, M, Pardon, E, Cregger, C, et al. Structures of P‐glycoprotein reveal its conformational flexibility and an epitope on the nucleotide‐binding domain. Proc Natl Acad Sci U S A 2013, 110:13386–13391.
Seelig, A. How does P‐glycoprotein recognize its substrates? Int J Clin Pharmacol Ther 1998, 36:50–54.
Pearce, HL, Safa, AR, Bach, NJ, Winter, MA, Cirtain, MC, Beck, WT. Essential features of the P‐glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci U S A 1989, 86:5128–5132.
Suzuki, T, Fukazawa, N, San‐nohe, K. Structure‐activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer. J Med Chem 1997, 40:2047–2052.
Hait, WN, Aftab, DT. Rational design and pre‐clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 1992, 43:103–107.
Schwaha, R, Ecker, GF. Use of shape similarities for the classification of P‐glycoprotein substrates and nonsubstrates. Future Med Chem 2011, 3:1117–1128.
Wang, Z, Chen, Y, Liang, H, Bender, A, Glen, RC, Yan, A. P‐glycoprotein substrate models using support vector machines based on a comprehensive data set. J Chem Inf Model 2011, 51:1447–1456.
Didziapetris, R, Japertas, P, Avdeef, A, Petrauskas, A. Classification analysis of P‐glycoprotein substrate specificity. J Drug Target 2003, 11:391–406.
Broccatelli, F. QSAR models for P‐glycoprotein transport based on a highly consistent data set. J Chem Inf Model 2012, 52:2462–2470.
Desai, PV, Sawada, GA, Watson, IA, Raub, TJ. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P‐glycoprotein efflux. Mol Pharm 2013, 10:1249–1261.
Desai, PV, Raub, TJ, Blanco, M‐J. How hydrogen bonds impact P‐glycoprotein transport and permeability. Bioorg Med Chem Lett 2012, 22:6540–6548.
Levatić, J, Curak, J, Kralj, M, Smuc, T, Osmak, M, Supek, F. Accurate models for P‐Gp drug recognition induced from a cancer cell line cytotoxicity screen. J Med Chem 2013, 56:5691–5708.
Broccatelli, F, Carosati, E, Neri, A, Frosini, M, Goracci, L, Oprea, TI, Cruciani, G. A novel approach for predicting P‐glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 2011, 54:1740–1751.
Ferreira, RJ, dos Santos, DJVA, Ferreira, M‐JU, Guedes, RC. Toward a better pharmacophore description of P‐glycoprotein modulators, based on macrocyclic diterpenes from euphorbia species. J Chem Inf Model 2011, 51:1315–1324.
Leong, MK, Chen, H‐B, Shih, Y‐H. Prediction of promiscuous P‐glycoprotein inhibition using a novel machine learning scheme. PLoS One 2012, 7:e33829.
Wiese, M, Pajeva, IK. Structure‐activity relationships of multidrug resistance reversers. Curr Med Chem 2001, 8:685–713.
Klepsch, F, Vasanthanathan, P, Ecker, GF. Ligand and structure‐based classification models for prediction of P‐glycoprotein inhibitors. J Chem Inf Model 2014, 54:218–229.
Tan, W, Mei, H, Chao, L, Liu, T, Pan, X, Shu, M, Yang, L. Combined QSAR and molecule docking studies on predicting P‐glycoprotein inhibitors. J Comput Aided Mol Des 2013, 27:1067–1073.
Sousa, IJ, Ferreira, M‐JU, Molnár, J, Fernandes, MX. QSAR studies of macrocyclic diterpenes with P‐glycoprotein inhibitory activity. Eur J Org Chem 2012, 48:542–553.
Madhavan, T, Gadhe, CG, Kothandan, G, Cho, SJ. Enhancement of P‐gylcoprotein modulators of arylmethylamine‐phenyl derivatives: an integrative modeling approach. Med Chem Res 2012, 22:2511–2523.
Jabeen, I, Wetwitayaklung, P, Chiba, P, Pastor, M, Ecker, GF. 2D‐ and 3D‐QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]‐oxazines as inhibitors of the multidrug transporter P‐glycoprotein. J Comput Aided Mol Des 2013, 27:161–171.
Brincat, JP, Broccatelli, F, Sabatini, S, Frosini, M, Neri, A, Kaatz, GW, Cruciani, G, Carosati, E. Ligand promiscuity between the efflux pumps human P‐glycoprotein and S. aureus NorA. ACS Med Chem Lett 2012, 3:248–251.
Zhu, T, Chen, J, Yang, J. Some substrates of P‐glycoprotein targeting β‐amyloid clearance by quantitative structure‐activity relationship (QSAR)/membrane‐interaction (MI)‐QSAR analysis. Adv Biosci Biotechnol 2013, 4:872–895.
Lagunin, AA, Gloriozova, TA, Dmitriev, AV, Volgina, NE, Poroikov, VV. Computer evaluation of drug interactions with P‐glycoprotein. Bull Exp Biol Med 2013, 154:521–524.
Poongavanam, V, Haider, N, Ecker, GF. Fingerprint‐based in silico models for the prediction of P‐glycoprotein substrates and inhibitors. Bioorg Med Chem 2012, 20:5388–5395.
Rapposelli, S, Coi, A, Imbriani, M, Bianucci, AM. Development of classification models for identifying “true” P‐glycoprotein (P‐Gp) inhibitors through inhibition, ATPase activation and monolayer efflux assays. Int J Mol Sci 2012, 13:6924–6943.
Verma, J, Khedkar, VM, Coutinho, EC. 3D‐QSAR in drug design—a review. Curr Top Med Chem 2010, 10:95–115.
Clay, AT, Sharom, FJ. Lipid bilayer properties control membrane partitioning, binding, and transport of P‐glycoprotein substrates. Biochemistry 2013, 52:343–354.
Kuntz, ID, Chen, K, Sharp, KA, Kollman, PA. The maximal affinity of ligands. Proc Natl Acad Sci U S A 1999, 96:9997–10002.
Chang, G. RETRACTED: structure of MsbA from vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. J Mol Biol 2003, 330:419–430.
Chang, G, Roth, CB. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001, 293:1793–1800.
Chang, G. Retraction of “Structure of MsbA from vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation” [J. Mol. Biol. (2003)330 419–430]. J Mol Biol 2007, 369:596.
Chang, G, Roth, CB, Reyes, CL, Pornillos, O, Chen, Y‐J, Chen, AP. Retraction of “Structure Pf MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporter” [Science (2001) 293 1793–1800]. Science 2006, 314:1875.
Locher, KP, Lee, AT, Rees, DC. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 2002, 296:1091–1098.
Dawson, RJP, Locher, KP. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP‐PNP. FEBS Lett 2007, 581:935–938.
Ward, A, Reyes, CL, Yu, J, Roth, CB, Chang, G. Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc Natl Acad Sci U S A 2007, 104:19005–19010.
Jin, MS, Oldham, ML, Zhang, Q, Chen, J. Crystal structure of the multidrug transporter P‐glycoprotein from Caenorhabditis elegans. Nature 2012, 490:566–569.
Loo, TW, Clarke, DM. Drug rescue distinguishes between different structural models of human P‐glycoprotein. Biochemistry 2013, 52:7167–7169.
Shintre, CA, Pike, ACW, Li, Q, Kim, J‐I, Barr, AJ, Goubin, S, Shrestha, L, Yang, J, Berridge, G, Ross, J, et al. Structures of ABCB10, a human ATP‐binding cassette transporter in Apo‐ and nucleotide‐bound states. Proc Natl Acad Sci U S A 2013, 110:9710–9715.
Chen, L, Morrow, JK, Tran, HT, Phatak, SS, Du‐Cuny, L, Zhang, S. From laptop to benchtop to bedside: structure‐based drug design on protein targets. Curr Pharm Des 2012, 18:1217–1239.
Anderson, AC. The process of structure‐based drug design. Chem Biol 2003, 10:787–797.
Dolghih, E, Bryant, C, Renslo, AR, Jacobson, MP. Predicting binding to P‐glycoprotein by flexible receptor docking. PLoS Comput Biol 2011, 7:e1002083.
Loo, TW, Bartlett, MC, Clarke, DM. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P‐glycoprotein. J Biol Chem 2003, 278:39706–39710.
Klepsch, F, Chiba, P, Ecker, GF. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P‐glycoprotein. PLoS Comput Biol 2011, 7:e1002036.
Jabeen, I, Wetwitayaklung, P, Klepsch, F, Parveen, Z, Chiba, P, Ecker, GF. Probing the stereoselectivity of P‐glycoprotein‐synthesis, biological activity and ligand docking studies of a set of enantiopure benzopyrano[3,4‐b][1,4]oxazines. Chem Commun 2011, 47:2586–2588.
Jabeen, I, Pleban, K, Rinner, U, Chiba, P, Ecker, GF. Structure‐activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone‐type inhibitors of the multidrug transporter P‐glycoprotein. J Med Chem 2012, 55:3261–3273.
Palmeira, A, Vasconcelos, MH, Paiva, A, Fernandes, MX, Pinto, M, Sousa, E. Dual Inhibitors of P‐glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochem Pharmacol 2012, 83:57–68.
Schwede, T. SWISS‐MODEL: an automated protein homology‐modeling server. Nucleic Acids Res 2003, 31:3381–3385.
Singh, DV, Godbole, MM, Misra, K. A plausible explanation for enhanced bioavailability of P‐Gp substrates in presence of piperine: simulation for next generation of P‐Gp inhibitors. J Mol Model 2013, 19:227–238.
Pajeva, IK, Sterz, K, Christlieb, M, Steggemann, K, Marighetti, F, Wiese, M. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P‐glycoprotein. ChemMedChem 2013, 8:1701–1713.
Pajeva, IK, Hanl, M, Wiese, M. Protein contacts and ligand binding in the inward‐facing model of human P‐glycoprotein. ChemMedChem 2013, 8:748–762.
Pajeva, I, Wiese, M. %22Application of in silico methods to study ABC transporters involved in multidrug resistance%22. In: Miteva, MA, ed. In‐Silico Lead Discovery. Paris: Bentham Science Publishers Ltd; 2011, 144–162.
Ferreira, RJ, Ferreira, M‐JU, dos Santos, DJVA. Molecular docking characterizes substrate‐binding sites and efflux modulation mechanisms within P‐glycoprotein. J Chem Inf Model 2013, 53:1747–1760.
Jara, GE, Vera, DMA, Pierini, AB. Binding of modulators to mouse and human multidrug resistance P‐glycoprotein. A computational study. J Mol Graph Model 2013, 46:10–21.
Wise, JG. Catalytic transitions in the human MDR1 P‐glycoprotein drug binding sites. Biochemistry 2012, 51:5125–5141.
Loo, TW, Clarke, DM. Identification of residues within the drug‐binding domain of the human multidrug resistance P‐glycoprotein by cysteine‐scanning mutagenesis and reaction with dibromobimane. J Biol Chem 2000, 275:39272–39278.
Loo, TW, Clarke, DM. Identification of residues in the drug‐binding domain of human P‐glycoprotein. Analysis of transmembrane segment 11 by cysteine‐scanning mutagenesis and inhibition by dibromobimane. J Biol Chem 1999, 274:35388–35392.
Loo, TW, Clarke, DM. Defining the drug‐binding site in the human multidrug resistance P‐glycoprotein using a methanethiosulfonate analog of verapamil, MTS‐Verapamil. J Biol Chem 2001, 276:14972–14979.
Shityakov, S, Förster, C. Multidrug resistance protein P‐Gp interaction with nanoparticles fullerenes and carbon nanotube) to assess their drug delivery potential: a theoretical molecular docking study. Int J Comput Biol Drug Des 2013, 6:343–357.
Xu, X, Li, R, Ma, M, Wang, X, Wang, Y, Zou, H. Multidrug resistance protein P‐glycoprotein does not recognize nanoparticle C60: experiment and modeling. Soft Matter 2012, 8:2915–2923.
Prajapati, R, Singh, U, Patil, A, Khomane, KS, Bagul, P, Bansal, AK, Sangamwar, AT. In silico model for P‐glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies. J Comput Aided Mol Des 2013, 27:347–363.
Cleave, SSA, Panda, R, Suresh, PK. In silico exploration of phenytoin binding site in two catalytic states of human P‐glycoprotein models. Indian J Biochem Biophys 2013, 50:7–13.
Yamaguchi, H, Kidachi, Y, Kamiie, K, Noshita, T, Umetsu, H. Homology modeling and structural analysis of human P‐glycoprotein. Bioinformation 2012, 8:1066–1074.
Yang, C, Zhang, T, Li, Z, Xu, L, Liu, F, Ruan, J, Liu, K, Zhang, Z. P‐glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. Toxicol Appl Pharmacol 2013, 273:561–568.
Tajima, Y, Nakagawa, H, Tamura, A, Kadioglu, O, Satake, K, Mitani, Y, Murase, H, Regasini, LO, da Silva Bolzani, V, Ishikawa, T, et al. Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine 2014, 21:323–332.
Vispute, SG, Chen, J‐J, Sun, Y‐L, Sodani, KS, Singh, S, Pan, Y, Talele, T, Ashby, CR Jr, Chen, Z‐S. Vemurafenib (PLX4032, Zelboraf®), a BRAF inhibitor, modulates ABCB1‐, ABCG2‐, and ABCC10‐mediated multidrug resistance. J Can Res Update 2013, 2:306–317.
Martinez, L, Arnaud, O, Henin, E, Tao, H, Chaptal, V, Doshi, R, Andrieu, T, Dussurgey, S, Tod, M, Di Pietro, A, et al. Understanding polyspecificity within the substrate‐binding cavity of the human multidrug resistance P‐glycoprotein. FEBS J 2014, 281:673–682.
Singh, S, Prasad, NR, Kapoor, K, Chufan, EE, Patel, BA, Ambudkar, SV, Talele, TT. Design, synthesis, and biological evaluation of (S)‐valine thiazole‐derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P‐glycoprotein (ABCB1). ChemBioChem 2014, 15:157–169.
Li, X, Hu, J, Wang, B, Sheng, L, Liu, Z, Yang, S, Li, Y. Inhibitory effects of herbal constituents on P‐glycoprotein in vitro and in vivo: herb‐drug interactions mediated via P‐Gp. Toxicol Appl Pharmacol 2013, 275:163–175.
Vilas‐Boas, V, Silva, R, Palmeira, A, Sousa, E, Ferreira, LM, Branco, PS, Carvalho, F, Bastos, M d L, Remião, F. Development of novel rifampicin‐derived P‐glycoprotein activators/inducers. Synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate. PLoS One 2013, 8:e74425.
Marcoux, J, Wang, SC, Politis, A, Reading, E, Ma, J, Biggin, PC, Zhou, M, Tao, H, Zhang, Q, Chang, G, et al. Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. Proc Natl Acad Sci U S A 2013, 110:9704–9709.
Lucas, X, Simon, S, Schubert, R, Günther, S. Discovery of the inhibitory effect of a phosphatidylinositol derivative on p‐glycoprotein by virtual screening followed by in vitro cellular studies. PLoS One 2013, 8:e60679.
Morris, GM, Huey, R, Lindstrom, W, Sanner, MF, Belew, RK, Goodsell, DS, Olson, AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009, 30:2785–2791.
Halgren, TA, Murphy, RB, Friesner, RA, Beard, HS, Frye, LL, Pollard, WT, Banks, JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004, 47:1750–1759.
Trott, O, Olson, AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010, 31:455–461.
Verdonk, ML, Cole, JC, Hartshorn, MJ, Murray, CW, Taylor, RD. Improved protein‐ligand docking using GOLD. Proteins 2003, 52:609–623.
Hrycyna, CA, Airan, LE, Germann, UA, Ambudkar, SV, Pastan, I, Gottesman, MM. Structural flexibility of the linker region of human P‐glycoprotein permits ATP hydrolysis and drug transport. Biochemistry 1998, 37:13660–13673.
Sato, T, Kodan, A, Kimura, Y, Ueda, K, Nakatsu, T, Kato, H. Functional role of the linker region in purified human P‐glycoprotein. FEBS J 2009, 276:3504–3516.
Caffrey, M. Membrane protein crystallization. J Struct Biol 2003, 142:108–132.
Lacapère, J‐J, Pebay‐Peyroula, E, Neumann, J‐M, Etchebest, C. Determining membrane protein structures: still a challenge!. Trends Biochem Sci 2007, 32:259–270.
Lee, AG. Lipid–protein interactions in biological membranes: a structural perspective. Biochim Biophys Acta 2003, 1612:1–40.
Klappe, K, Hummel, I, Hoekstra, D, Kok, JW. Lipid dependence of ABC transporter localization and function. Chem Phys Lipids 2009, 161:57–64.
Ivetac, A, Sansom, MSP. Molecular dynamics simulations and membrane protein structure quality. Eur Biophys J 2008, 37:403–409.
Aänismaa, P, Gatlik‐Landwojtowicz, E, Seelig, A. P‐glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle. Biochemistry 2008, 47:10197–10207.
Gunaydin, H, Weiss, MM, Sun, YD. Novo prediction of P‐glycoprotein‐mediated efflux liability for druglike compounds. ACS Med Chem Lett 2013, 4:108–112.
Ma, J, Biggin, PC. Substrate versus inhibitor dynamics of P‐glycoprotein. Proteins 2013, 81:1653–1668.
Oliveira, AS, Baptista, AM, Soares, CM. Conformational changes induced by ATP‐hydrolysis in an ABC transporter: a molecular dynamics study of the Sav1866 exporter. Proteins 2011, 79:1977–1990.
Moradi, M, Tajkhorshid, E. Mechanistic picture for conformational transition of a membrane transporter at atomic resolution. Proc Natl Acad Sci U S A 2013, 110:18916–18921.
Loo, TW. The packing of the transmembrane segments of human multidrug resistance P‐glycoprotein is revealed by disulfide cross‐linking analysis. J Biol Chem 2000, 275:5253–5256.
Urbatsch, IL, Gimi, K, Wilke‐Mounts, S, Lerner‐Marmarosh, N, Rousseau, ME, Gros, P, Senior, AE. Cysteines 431 and 1074 are responsible for inhibitory disulfide cross‐linking between the two nucleotide‐binding sites in human P‐glycoprotein. J Biol Chem 2001, 276:26980–26987.
Yuan, YR, Blecker, S, Martsinkevich, O, Millen, L, Thomas, PJ, Hunt, JF. The crystal structure of the MJ0796 ATP‐binding cassette. Implications for the structural consequences of ATP hydrolysis in the active site of an ABC transporter. J Biol Chem 2001, 276:32313–32321.
Smith, PC, Karpowich, N, Millen, L, Moody, JE, Rosen, J, Thomas, PJ, Hunt, JF. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 2002, 10:139–149.
Zaitseva, J, Oswald, C, Jumpertz, T, Jenewein, S, Wiedenmann, A, Holland, IB, Schmitt, L. A structural analysis of asymmetry required for catalytic activity of an ABC‐ATPase domain dimer. EMBO J 2006, 25:3432–3443.
Furukawa‐Hagiya, T, Furuta, T, Chiba, S, Sohma, Y, Sakurai, M. The power stroke driven by ATP binding in CFTR as studied by molecular dynamics simulations. J Chem Phys B 2013, 117:83–93.
Higgins, CF, Linton, KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004, 11:918–926.
Jones, PM, George, AM. Opening of the ADP‐bound active site in the ABC transporter ATPase dimer: evidence for a constant contact, alternating sites model for the catalytic cycle. Proteins 2009, 75:387–396.
Oliveira, ASF, Baptista, AM, Soares, CM. Insights into the molecular mechanism of an abc transporter: conformational changes in the NBD dimer of MJ0796. J Phys Chem B 2010, 114:5486–5496.
Damas, JM, Oliveira, ASF, Baptista, AM, Soares, CM. Structural consequences of ATP hydrolysis on the ABC transporter NBD dimer: molecular dynamics studies of HlyB. Protein Sci 2011, 20:1220–1230.
George, AM, Jones, PM. An asymmetric post‐hydrolysis state of the ABC transporter ATPase dimer. PLoS One 2013, 8:e59854.
Becker, J‐P, Van Bambeke, F, Tulkens, PM, Prévost, M. Dynamics and structural changes induced by ATP binding in SAV1866, a bacterial ABC exporter. J Phys Chem B 2010, 114:15948–15957.
Jones, PM, George, AM. Molecular‐dynamics simulations of the ATP/apo state of a multidrug ATP‐binding cassette transporter provide a structural and mechanistic basis for the asymmetric occluded state. Biophys J 2011, 100:3025–3034.
Aittoniemi, J, de Wet, H, Ashcroft, FM, Sansom, MSP. Asymmetric switching in a homodimeric ABC transporter: a simulation study. PLoS Comput Biol 2010, 6:e1000762.
Oloo, EO, Tieleman, DP. Conformational transitions induced by the binding of MgATP to the vitamin B12 ATP‐binding cassette (ABC) transporter BtuCD. J Biol Chem 2004, 279:45013–45019.
Garrigues, A, Escargueil, AE, Orlowski, S. The multidrug transporter, P‐glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A 2002, 99:10347–10352.
Loo, TW, Clarke, DM. The transmembrane domains of the human multidrug resistance P‐glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem 1999, 274:24759–24765.
Rosenberg, MF, Velarde, G, Ford, RC, Martin, C, Berridge, G, Kerr, ID, Callaghan, R, Schmidlin, A, Wooding, C, Linton, KJ, et al. Repacking of the transmembrane domains of P‐glycoprotein during the transport ATPase cycle. EMBO J 2001, 20:5615–5625.
Kleywegt, GJ. Validation of protein crystal structures. Acta Crystallogr D Biol Crystallogr 2000, 56:249–265.
Biggin, PC, Bond, PJ. Molecular dynamics simulations of membrane proteins. Methods Mol Biol 2008, 443:147–160.
Fan, H, Mark, AE. Relative stability of protein structures determined by X‐ray crystallography or NMR spectroscopy: a molecular dynamics simulation study. Proteins 2003, 53:111–120.
Brunger, AT, Adams, PD. %22Refinement of X‐ray crystal structures%22. In: Egelman, EH, ed. Comprehensive Biophysics. Elsevier Inc; 2012, 105–115.
Burnley, BT, Afonine, PV, Adams, PD, Gros, P. Modelling dynamics in protein crystal structures by ensemble refinement. Elife 2012, 1:e00311.
O`Mara, ML, Tieleman, DP. P‐glycoprotein models of the Apo and ATP‐bound states based on homology with Sav1866 and MalK. FEBS Lett 2007, 581:4217–4222.
Chang, S‐Y, Liu, F‐F, Dong, X‐Y, Sun, Y. Molecular insight into conformational transmission of human P‐glycoprotein. J Chem Phys 2013, 139:225102.
Wen, P‐C, Verhalen, B, Wilkens, S, Mchaourab, HS, Tajkhorshid, E. On the origin of large flexibility of P‐glycoprotein in the inward‐facing state. J Biol Chem 2013, 288:19211–19220.
O`Mara, ML, Mark, AE. The effect of environment on the structure of a membrane protein: P‐glycoprotein under physiological conditions. J Chem Theory Comput 2012, 8:3964–3976.
Ferreira, RJ, Ferreira, M‐JU, dos Santos, DJVA. Insights on P‐glycoprotein`s efflux mechanism obtained by molecular dynamics simulations. J Chem Theory Comput 2012, 8:1853–1864.
Ferreira, RJ, Ferreira, M‐JU, dos Santos, DJVA. Assessing the stabilization of P‐glycoprotein`s nucleotide‐binding domains by the linker, using molecular dynamics. Mol Inf 2013, 32:529–540.
Zhang, J, Sun, T, Liang, L, Wu, T, Wang, Q. Drug promiscuity of P‐glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin. Soft Matter 2014, 10:438.
Watanabe, Y, Hsu, W‐L, Chiba, S, Hayashi, T, Furuta, T, Sakurai, M. Dynamics and structural changes induced by ATP and/or substrate binding in the inward‐facing conformation state of P‐glycoprotein. Chem Phys Lett 2013, 557:145–149.
Liu, M, Hou, T, Feng, Z, Li, Y. The flexibility of P‐glycoprotein for its poly‐specific drug binding from molecular dynamics simulations. J Biomol Struct Dyn 2013, 31:612–629.
Seelig, A. A general pattern for substrate recognition by P‐glycoprotein. Eur J Biochem 1998, 251:252–261.
Dolghih, E, Jacobson, MP. Predicting efflux ratios and blood‐brain barrier penetration from chemical structure: combining passive permeability with active efflux by P‐glycoprotein. ACS Chem Neurosci 2013, 4:361–367.
Reis, M, Ferreira, RJ, Serly, J, Duarte, N, Madureira, AM, dos Santos, DJVA, Molnár, J, Ferreira, M‐JU. Colon adenocarcinoma multidrug resistance reverted by euphorbia diterpenes: structure‐activity relationships and pharmacophore modeling. Anticancer Agents Med Chem 2012, 12:1015–1024.
Nagar, S, Tucker, J, Weiskircher, EA, Bhoopathy, S, Hidalgo, IJ, Korzekwa, K. Compartmental models for apical efflux by P‐glycoprotein‐part 1: evaluation of model complexity. Pharm Res 2014, 31:347–359.
Korzekwa, K, Nagar, S. Compartmental models for apical efflux by P‐glycoprotein: part 2‐a theoretical study on transporter kinetic parameters. Pharm Res 2013, 31:335–346.
Neuhoff, S, Yeo, KR, Barter, Z, Jamei, M, Turner, DB, Rostami‐Hodjegan, A. Application of permeability‐limited physiologically‐based pharmacokinetic models: part I‐digoxin pharmacokinetics incorporating P‐glycoprotein‐mediated efflux. J Pharm Sci 2013, 102:3145–3160.
Neuhoff, S, Yeo, KR, Barter, Z, Jamei, M, Turner, DB, Rostami‐Hodjegan, A. Application of permeability‐limited physiologically‐based pharmacokinetic models: part II—prediction of P‐glycoprotein mediated drug‐drug interactions with digoxin. J Pharm Sci 2013, 102:3161–3173.